XML 28 R17.htm IDEA: XBRL DOCUMENT v3.20.2
Revenues from Contracts with Customers
3 Months Ended
Sep. 30, 2020
Revenue from Contract with Customer [Abstract]  
Revenues from Contracts with Customers REVENUES FROM CONTRACTS WITH CUSTOMERS
Disaggregation of Revenue from Contracts with Customers—The disaggregation of revenue by segment and product is depicted for the periods presented below, and is consistent with how the Company evaluates its financial performance:

Three Months Ended September 30,
(in thousands)20202019
Senior:
Commission revenue:
Medicare advantage$48,731 $20,187 
Medicare supplement7,992 4,151 
Prescription drug plan615 376 
Dental, vision, and health2,723 1,001 
Other commission revenue459 (52)
Total commission revenue60,520 25,663 
Production bonus and other revenue12,679 1,921 
Total Senior revenue73,199 27,584 
Life:
Commission revenue:
Term19,376 18,584 
Final expense17,637 3,493 
Ancillary584 569 
Total commission revenue37,597 22,646 
Production bonus and other revenue5,226 4,961 
Total Life revenue42,823 27,607 
Auto & Home:
Total commission revenue8,613 9,589 
Production bonus and other revenue925 463 
Total Auto & Home revenue9,538 10,052 
Eliminations:
Total commission revenue(185)(76)
Production bonus and other revenue(1,206)— 
Total Elimination revenue(1,391)(76)
Total commission revenue106,545 57,822 
Total production bonus and other revenue17,624 7,345 
Total revenue$124,169 $65,167 

Contract Balances—After a policy is sold, the Company has no material additional or recurring obligations to the policyholder or the insurance carrier. As such, there are no contract liabilities recorded in the consolidated balance sheets. As there is no activity in the contract asset balances other than the movement over time between long-term and short-term commissions receivable and accounts receivable as the policy is renewed, a separate roll forward other than what is shown on the consolidated balance sheets is not relevant. Cumulative revenue catch-up adjustments related to changes in the estimates of transaction prices were not material for the three months ended September 30, 2020 and 2019.
Production Bonuses and Other—During the three months ended September 30, 2020, the Company received advance payments of fiscal year 2021 marketing development funds, which will be amortized over the course of the year based on policies sold. As of September 30, 2020, there was an unamortized balance remaining of $19.2 million recorded in other current liabilities in the consolidated balance sheet.